Physician profile
Catherine Majcher
NPI 1861864175
$3,803.12
in general payments reported to CMS, 2019-2025
36 companies · $916 in 2025
The $916 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $738 · 2023: $457 · 2024: $712 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700 · Education: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.38 |
| Education | $384.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $835.55 | 2021-2025 | |
| Astellas Pharma US INC | $410.57 | 2022-2025 | Xospata, Vyloy |
| Abbvie INC. | $303.26 | 2021-2025 | |
| Incyte Corporation | $294.90 | 2021-2025 | Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $210.33 | 2021-2022 | |
| Gilead Sciences, INC. | $175.88 | 2022-2025 | Trodelvy |
| Seagen INC. | $160.98 | 2021-2025 | |
| Lilly USA, LLC | $152.85 | 2021-2023 | Verzenio |
| Janssen Biotech, INC. | $107.22 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $98.85 | 2023-2025 | Iclusig |
| E.R. Squibb & Sons, L.L.C. | $97.60 | 2023-2025 | Opdivo |
| Pfizer INC. | $94.96 | 2021-2025 | |
| Amgen INC. | $86.20 | 2021-2022 | |
| Genzyme Corporation | $82.47 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $75.63 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $68.15 | 2023-2025 | Jemperli, Zejula |
| Agios Pharmaceuticals, INC. | $61.04 | 2025 | Pyrukynd |
| Daiichi Sankyo INC. | $50.79 | 2021-2025 | Vanflyta |
| Beigene USA, INC. | $36.32 | 2021 | |
| Pharmaessentia USA Corporation | $35.69 | 2025 | Besremi |
| Tersera Therapeutics LLC | $32.06 | 2025 | Zoladex |
| Astrazeneca Pharmaceuticals LP | $29.88 | 2024 | Imfinzi |
| Karyopharm Therapeutics INC. | $24.82 | 2022 | |
| Emd Serono, INC. | $23.45 | 2025 | |
| Eisai INC. | $23.34 | 2023 | |
| Geron Corporation | $23.04 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $22.92 | 2025 | |
| G1 Therapeutics, INC. | $22.53 | 2022 | |
| Fennec Pharmaceuticals, INC. | $22.45 | 2024 | Pedmark |
| Deciphera Pharmaceuticals INC. | $22.41 | 2021 | |
| Genentech USA, INC. | $21.28 | 2023 | Tecentriq |
| Morphosys, US INC. | $21.02 | 2022 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Puma Biotechnology, INC. | $20.61 | 2025 | |
| Sobi, INC | $19.31 | 2025 | |
| Melinta Therapeutics, LLC | $13.76 | 2024 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Majcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.